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L ipopolysaccharide (LPS), a fat-polysaccharide complex in the outer cell membrane of Gram-negative bacteria, 1 causes clinical symptoms of fever, low blood pressure, inflammation, shock, angioedema, and multiple organ failure during bacterial infection. 2 Septic shock is the most common cause of death in the intensive care unit, with mortality of 40% to 70%. Intravenous injection of larger doses of LPS (maximum 1 mg) in humans resulted in severe hypotension and multiorgan dysfunction within 2 hours of administration. 3 Because current therapy is limited to blood transfusion, plasmapheresis, and antibiotic administration, novel therapeutic approaches are needed. Toll-like receptor (TLR) 4, LPS receptor, recognizes lipid A in LPS by myeloid differentiation factor 2. [4] [5] [6] [7] Myeloid differentiation factor 2 is an important link between TLR4 and LPS signaling pathways. 8, 9 Administration of LPS triggers the release of many cytokines, such as vascular endothelial growth factor, tumor necrosis factor-α, interleukin (IL)-1, IL-6, and IL-8. [10] [11] [12] Although the pathogenesis of LPS-induced diseases is complex, inflammation induced by LPS is known to be largely mediated by the epithelial growth factor receptor (EGFR) pathway. Indeed, LPS induced the expression of vascular cell adhesion molecule-1 (VCAM-1) via the EGFR/Akt pathway. 13, 14 In addition, LPS induced the production of reactive oxygen species (ROS) through TLR4, 15 whereas EGFR facilitated production of ROS. 16 Recently, it was reported that EGFR ubiquitination via casitas B-lineage lymphoma (c-Cbl) is an important step in the mechanism of EGFR expression. 17 Downregulation of conjugation between Src homology domain 2-containing inositol 5′-phosphatase 2 (SHIP2) and EGFR occurs during c-Cbl binding to EGFR. 18 The EGFR-c-Cbl complex is broken down by proteasomal endocytosis. 19, 20 Interestingly, SHIP2 also binds to Tyr 1356 of c-Met, the hepatocyte growth factor (HGF) [21] [22] [23] [24] [25] [26] [27] receptor, and c-Met is broken down by proteasomes. 28 Based on these data, our previous study demonstrated that HGF inhibited oxidative stress induced by angiotensin II via EGFR degradation by ubiquitination via the binding of SHIP2 to c-Met. 29 Thus, in the present study, we found that in response to LPS stimulation, HGF inhibited VCAM-1 expression, ROS production, and vascular injury via EGFR degradation.
Materials and Methods

Materials
LPS (Escherichia coli 0.55:B5) was purchased from Sigma-Aldrich. MG-132 was purchased from Calbiochem-Novabiochem Int. Evans blue was purchased from Sigma. HGF was purchased from Calbiochem.
Animals
Male HGF transgenic (TG) mice aged 8 to 10 weeks were used in these experiments. HGF TG mice were generated from C57BL6 mice with overexpression of cardiac-specific (α-myosin heavy chaindriven) human HGF gene, producing high levels of heart-derived serum HGF. 30 There were no significant differences in cardiac function between wild-type (WT) and HGF TG mice under basal conditions. 29 LPS diluted with PBS infusion (50 mg/kg) was administered intravenously (via a neck vein). WT mice were treated with erlotinib (F. Hoffman-La Roche, Nutley, NJ) by oral administration ( Figure  II in the online-only Data Supplement). After suspension in vehicle (0.2% carboxymethyl cellulose containing 0.1% Tween 80), erlotinib was sonicated for 5 minutes and homogenized for 7 minutes before administration. WT mice were treated with erlotinib (30 mg/kg) by oral infusion every 8 hours. Second, erlotinib administration was performed at the same time as LPS administration. All procedures were performed in accordance with the guidelines of the Institutional Animal Committee of Osaka University School of Medicine.
Cell Culture
Human aortic vascular smooth muscle cells (VSMCs) and human aortic endothelial cells (HAECs) were purchased from LONZA Walkersville Inc. VSMCs were cultured in smooth muscle basal medium with supplements and 5% fetal bovine serum. HAECs were cultured in endothelial basal medium with supplements and 5% fetal bovine serum. After 24-hour starvation, VSMCs were stimulated with several concentrations of LPS, with or without pretreatment for 12 hours with HGF (20 ng/mL). After 24 hours of starvation, HAECs were stimulated with several concentrations of LPS with or without pretreatment for 3 hours with HGF (20 ng/mL).
Western Blotting
Protein extracts (8 μg) were resolved on 10% SDS-PAGE and transferred to nitrocellulose membrane. Western blotting was performed, as previously described. 31 VCAM-1 antibody, α-tubulin antibody, Akt1/2 antibody, phospho-IκB-α antibody, IκB-α antibody, and Duox1 antibody were obtained from Santa Cruz Biotechnology, Inc (CA). EGF receptor antibody, phospho Akt (Ser 473) antibody, phospho p44/42 mitogen-activated protein kinase (Thr202/Tyr204) antibody, and p44/42 mitogen-activated protein kinase (Thr202/Tyr204) antibody were obtained from Cell Signaling (Boston, MA). c-Cbl antibody was obtained from BD Pharmingen (Franklin Lake). Western blotting images were quantified using the software package ImageJ.
Immunoprecipitation
In the initial immunoprecipitation experiments, 20 μL of protein G agarose (Sigma-Aldrich) was added to cell extracts prepared in 300 μg protein. Then, 2 μL SHIP2 antibody (Cell Signaling; Figure 2D ) and EGF receptor antibody (Cell Signaling; Figure 3A) were added to the supernatant and stirred at 4°C overnight. The agarose was washed 3× with radioimmunoprecipitation assay buffer, protease inhibitor, and 2 μmol/L NaF. The protein was eluted from protein G agarose in 12 μL SDS-PAGE sample buffer. The supernatant was used for Western blotting.
Small Interfering RNA Transfection
VSMCs (passages 7 to 9) were used. Using a Nucleofector device (Amaxa, Gaithersburgm) and Basic Nucleofector Kit for Primary Smooth Muscle Cells (Amaxa), VSMCs were transfected with EGFR small interfering RNA (siRNA; Santa Cruz Biotechnology, Inc). VSMCs incubated for 48 hours after siRNA transfection were used in this experiment.
Immunofluorescence
Forty-eight hours after seeding of VSMCs on PLL-coated 35-mm dishes (Matsunami Glass Ind., Ltd), VSMCs were subjected to 24-hour serum starvation. For immunofluorescence, cells were fixed with 100% methanol, permeabilized with 0.2% Triton X-100, and blocked for 5 minutes in PBS containing goat serum (DakoCytomation, 1:200). After washing 3× with PBS, cells were incubated overnight with primary antibodies: EGF receptor antibody (Cell Signaling, 1:100) and c-Cbl antibody (BD Pharmingen, 1:100). Cells were then incubated for 1 hour with second antibody, Alexa Fluor 546 F (ab′) 2 fragment of goat anti-mouse IgG (Invitrogen, 1:250) and Alexa Fluor 488 F (ab′) 2 fragment of goat anti-rabbit IgG (Invitrogen, 1:250). After washing with PBS, cells were covered with Vectashield (Vector Laboratories) using a cover glass, and fluorescent micrographs were taken using a fluorescence microscope (KEYENCE BZ9000).
Dihydroethidium Fluorescence
In vivo, after mice were treated with LPS for 24 hours, they were euthanized under anesthesia with ketamine/xylazine and perfused with PBS. After aortic tissue blocks with optimum cutting temperature compound (Sakura) were made, 0.05-μm sections were obtained for examining dihydroethidium fluorescence. After 3 washes with PBS, sections were fixed with acetone, permeabilized with 0.2% Triton X-100, and washed with PBS again. After sections were incubated with dihydroethidium (Invitrogen, 1:500) for 30 minutes, they were washed 3× with PBS and covered with Vectashield using a cover glass. Fluorescent micrographs were taken using a fluorescence microscope.
In vitro, HAECs were incubated on a collagen type I-coated 6-well microplate (Iwaki Science Product Department, Asahi Glass Co, Ltd) for 48 hours after seeding, followed by 24-hour serum starvation. HAECs were stimulated with 50 μg/mL LPS with or without pretreatment for 3 hours with HGF (20 ng/mL). After 24 hours, cells were fixed with 100% methanol, permeabilized with 0.2% Triton X-100, and washed 3× with PBS. Afterward, cells were incubated with dihydroethidium (Invitrogen, 1:500) for 30 minutes, washed 3× with PBS, and covered with Vectashield using a cover glass. Then, fluorescent micrographs were taken using a fluorescence microscope.
Permeability to Evans Blue In Vivo
Permeability experiments were performed using previously established methods. 32 After mice were treated with LPS for 24 hours, they were injected in a neck vein with Evans blue (50 mg/kg) in PBS. After 30 minutes, mice were euthanized under anesthesia with ketamine/xylazine and perfused with 20 mL 4% formaldehyde in PBS. The abdominal aorta was excised, dried, and incubated in formaldehyde for 24 hours at 60°C to extract Evans blue. Absorbance at 620 nm was measured and normalized to the weight of the aorta.
Statistics
Statistical comparisons were performed using SPSS version 19.0 (SPSS Inc). All data were analyzed by the Levene test to determine the equality of variance. All values are expressed as mean+SEM, with statistical significance defined as P<0.05 for all studies.
Results
Molecular Mechanisms of Inhibition of LPS-Induced VCAM-1 Expression by HGF in Human VSMCs
We first examined the effects of HGF on LPS-induced expression of EGFR and VCAM-1 and phosphorylation of Akt and extracellular signal-regulated kinase (ERK) in human VSMCs. LPS significantly increased EGFR expression to 121.4+15.1% (stimulation with 10 μg/mL LPS, n=4) and 174.8+18.5% (stimulation with 50 μg/mL LPS, n=4) after LPS treatment for 24 hours. LPS stimulation also resulted in a significant increase in VCAM-1 in a dose-dependent manner to 143.3+13.5% (stimulation with 10 μg/mL LPS, n=4) and 204.5+32.8% (stimulation with 50 μg/mL LPS, n=4). Interestingly, the increase in EGFR and VCAM-1 was significantly inhibited by 12 hours of pretreatment with HGF (20 ng/mL) compared with stimulation with 50 μg/mL LPS alone ( Figure 1A-1C) . Similarly, the increase in phosphorylation of Akt (ser473) and ERK (thr202/ tyr204) was significantly inhibited by pretreatment with HGF (20 ng/mL) compared with LPS alone (Figure 1D and 1E) . The increase in VCAM-1 expression by LPS was mediated by EGFR, because transfection of EGFR siRNA resulted in attenuation of VCAM-1 expression (Figure 2A-2C ; P<0.05).
Therefore, we next focused on how HGF downregulated EGFR. Because SHIP2 is an important molecule involved in EGFR expression, 17 we focused on SHIP2 under HGF treatment. After cells were treated with LPS, conjugation between SHIP2 and EGFR reached a peak at 15 minutes ( Figure III in the online-only Data Supplement). Pretreatment with HGF for 12 hours significantly inhibited the translocation of SHIP2 to EGFR ( Figure 2D ). In addition, HGF pretreatment significantly enhanced the conjugation between EGFR and c-Cbl ( Figure 3A) . Importantly, HGF pretreatment resulted in colocation of EGFR and c-Cbl in the cytoplasm ( Figure 3B ). EGFR was mainly expressed in the plasma membrane, whereas EGFR was moved into the cytoplasm by endocytosis when EGFR bound to c-Cbl. The increase in c-Cbl binding to EGFR led to ubiquitination and degradation of EGFR. [17] [18] [19] To determine whether proteasome-mediated degradation of EGFR occurs, cells were treated with MG-132, a proteasome inhibitor, under LPS stimulation. HGF treatment 
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significantly stimulated EGFR degradation under LPS stimulation, whereas MG-132 significantly inhibited EGFR degradation induced by HGF ( Figure 3C ). These data suggest that HGF may inhibit the inflammation induced by LPS, by stimulation of EGFR degradation, leading to inhibition of VCAM expression.
Inhibition of LPS-Induced Inflammation and Organ Injury in HGF TG Mice
To confirm the inhibition of LPS-induced inflammation by HGF in vivo, we used HGF TG mice. Mice were injected with 50 mg/kg LPS via a neck vein. LPS injection significantly induced EGFR and VCAM-1 protein expression in WT mice at 24 hours after injection. Similarly, phosphorylation of Akt, ERK, and IκB was significantly increased by LPS administration. Of importance, the increased expression of EGFR and VCAM-1 protein by LPS was significantly inhibited in HGF TG mice (Figure 4A-4C ; P<0.05). The phosphorylation of Akt, ERK, and IκB was also significantly inhibited in HGF TG mice (Figure 4D-4F ; P<0.05). These data support that HGF inhibited inflammation induced by HGF. Thus, we measured creatinine and blood urea nitrogen levels, markers of kidney function, as well as aspartate aminotransferase and alanine aminotransferase as markers of liver function, because LPS induced severe organ damage. [33] [34] [35] [36] [37] Levels of creatinine, blood urea nitrogen, aspartate aminotransferase, and alanine aminotransferase were significantly increased after LPS treatment for 24 hours in WT mice, whereas their levels were lower in HGF TG mice ( Figure  I in the online-only Data Supplement). In addition, because LPS induced ROS production in several organs, 38 we also determined ROS production in the kidney, liver, and lung using erlotinib, an EGFR tyrosine kinase inhibitor. A significant increase in ROS production in each organ was observed in WT mice after LPS treatment for 24 hours, whereas ROS production was significantly reduced in HGF TG mice and WT mice under treatment with oral administration of erlotinib ( Figure II in the online-only Data Supplement).
Prevention of LPS-Induced Vascular Injury in HGF TG Mice
Because LPS-induced vascular damage through ROS production in endothelial cells triggers lung injury, 39 we examined the effects of LPS stimulation on vascular cells in HGF TG mice. Similar to liver and kidney, a significant increase in ROS production by LPS was detected in the aorta of WT mice ( Figure 5A and 5B). In contrast, inhibition of ROS production was also observed in the aorta of HGF TG mice compared with WT mice. Similarly, Duox1 overexpression, which produces ROS in abdominal aorta with LPS injection, was inhibited in HGF TG mice ( Figure IV in the online-only Data Supplement). Inhibition of ROS production by HGF was confirmed using HAECs in vitro. As shown in Figure 5C and 5D, HGF pretreatment significantly inhibited LPS-induced ROS production in HAECs. Finally, we found that vascular permeability was significantly inhibited in HGF TG mice, whereas LPS injection induced vascular permeability in WT mice, using Evans blue injection ( Figure 5E and 5F). 
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LPS-induced cell toxicity is complex and unclear. However, the present data suggest that one of the important pathways is an EGFR-related pathway. The present study showed the inhibitory effect of the HGF/cMet system on inflammation both in vitro and in vivo. 40 There are many reports about the mechanism of LPS-induced inflammation. For example, Lin et al 14 showed that LPS induces VCAM-1 expression via the Src/EGFR/PI3-K/Akt pathway, consistent with the present study. They also reported that LPS induced VCAM-1 expression through mitogen-activated protein kinase and nuclear factor-κB in human tracheal smooth muscle cells. 13 At the same time, Koff et al showed that LPS induced EGFR activation via the TLR4-TNF-α converting enzyme pathway. 41, 42 These reports suggest that LPS induces inflammation via EGFR activation. The present data indicate that EGFR plays an important part in LPS-induced inflammation. To determine the effect of EGFR on LPS-induced inflammation, we used EGFR siRNA to inhibit EGFR signaling. After transfection of EGFR siRNA with LPS stimulation, the expression of VCAM-1, an inflammatory marker, decreased significantly. This suggests that activation of EGFR is absolutely imperative in the LPS-induced inflammation cascade and that HGF may inhibit inflammation induced by LPS through stimulation of EGFR degradation, leading to the inhibition of VCAM expression.
The most important finding of this study is the protective effects of HGF against multiple organ damage induced by LPS. HGF is a cytokine with multipotent faculties mediated by c-Met. 43 The negative action of HGF on angiotensin II signaling has been previously reported. 29, 44, 45 In those reports, HGF significantly inhibited inflammation via EGFR degradation on angiotensin II stimulation. Therefore, it is noteworthy to examine whether HGF inhibits LPS-induced inflammation via EGFR degradation, because there is no known effective The HGF/c-Met system is involved in the ubiquitin-proteasome system. EGFR ubiquitination via SHIP2 translocation is an important step in the mechanism of EGFR expression. 17 Downregula tion of conjugation between SHIP2 and EGFR leads to the binding of c-Cbl to EGFR. 18 The EGFR-c-Cbl complex is broken down by proteasomes via endocytosis. 19, 20 SHIP2 also binds to the Tyr 1356 residue of c-Met, which is also broken down by proteasomes. 21 These reports are consistent with the present study. HGF does not affect EGFR expression under basal conditions. Here, we showed that HGF and its receptor, c-Met, regulate LPS-induced inflammation by EGFR downregulation via ubiquitin-proteasome system. This article shows EGFR degradation by the inhibition of SHIP2 binding to EGFR, an increase in the binding of Cbl to EGFR, and an increase in the binding of ubiquitin to EGFR. Because there are sufficient amounts of intracellular SHIP2 under basal conditions, SHIP2 can bind to EGFR to preserve EGFR expression. But under LPS stimulation, a reasonable amount of SHIP2 might not be recruited to EGFR because of the increase in EGFR expression.
To determine the possibility that EGFR downregulation occurs via the ubiquitin-proteasome system, we used MG-132, a proteasome inhibitor, with LPS stimulation. HGF treatment significantly stimulated EGFR degradation with LPS stimulation, whereas MG-132 significantly abrogated EGFR degradation induced by HGF. Our results showed that HGF promotes SHIP2 recruitment not to EGFR but to c-Met under LPS stimulation ( Figure 6 ). Furthermore, the phosphoinositide 3-kinase inhibitor/Akt and mitogen-activated protein kinase/ERK pathways were inhibited by HGF-induced EGFR suppression. As a result, VCAM-1 expression was diminished by HGF both in vitro and in vivo. Furthermore, HGF TG significantly improved survival in LPS injection model ( Figure V in the online-only Data Supplement). To confirm the effect of LPS on survival rate, we used HGF TG mice and WT mice. Mice were injected with 50 or 150 mg/kg LPS through a neck vein. The 100-hour survival rate after LPS injection (50 mg/kg) in WT mice was 57% versus 89% in HGF TG mice. Thus, HGF TG mice had significantly better survival than WT mice (P<0.05).
In conclusion, the present data demonstrated that the HGF/ c-Met system prevented LPS-induced liver, renal, and vascular injuries through the inhibition of inflammation and ROS production, which was achieved via EGFR degradation by an E3 ubiquitin protein ligase, the Cbl-mediated ubiquitinproteasome system. Therefore, HGF/c-Met could interact with EGFR to maintain homeostasis of many organs in the immune system. A B Figure 6 . Epithelial growth factor receptor (EGFR) ubiquitination by hepatocyte growth factor (HGF)/c-Met system with lipopolysaccharide (LPS) stimulation. A, Under basal conditions, Src homology domain 2-containing inositol 5′-phosphatase 2 (SHIP2) prevented excess ubiquitination by inhibiting Cb1 binding to EGFR after LPS stimulation. B, The HGF/c-Met system inhibited SHIP2 translocation to EGFR after LPS stimulation through binding of SHIP2 to its own receptor, c-Met. Under these conditions, Cbl bound to EGFR significantly, which might degrade EGFR and prevent LPS signaling.
